JP2014534962A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534962A5
JP2014534962A5 JP2014535865A JP2014535865A JP2014534962A5 JP 2014534962 A5 JP2014534962 A5 JP 2014534962A5 JP 2014535865 A JP2014535865 A JP 2014535865A JP 2014535865 A JP2014535865 A JP 2014535865A JP 2014534962 A5 JP2014534962 A5 JP 2014534962A5
Authority
JP
Japan
Prior art keywords
composition
naglu
rhnaglu
protein
rhnaglu protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014535865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534962A (ja
JP6329483B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/059708 external-priority patent/WO2013055888A2/en
Publication of JP2014534962A publication Critical patent/JP2014534962A/ja
Publication of JP2014534962A5 publication Critical patent/JP2014534962A5/ja
Application granted granted Critical
Publication of JP6329483B2 publication Critical patent/JP6329483B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014535865A 2011-10-12 2012-10-11 組換えヒトｎａｇｌｕタンパク質およびその利用 Expired - Fee Related JP6329483B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546248P 2011-10-12 2011-10-12
US61/546,248 2011-10-12
PCT/US2012/059708 WO2013055888A2 (en) 2011-10-12 2012-10-11 Recombinant human naglu protein and uses thereof

Publications (3)

Publication Number Publication Date
JP2014534962A JP2014534962A (ja) 2014-12-25
JP2014534962A5 true JP2014534962A5 (OSRAM) 2015-11-26
JP6329483B2 JP6329483B2 (ja) 2018-05-23

Family

ID=48082738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535865A Expired - Fee Related JP6329483B2 (ja) 2011-10-12 2012-10-11 組換えヒトｎａｇｌｕタンパク質およびその利用

Country Status (18)

Country Link
US (3) US9579366B2 (OSRAM)
EP (1) EP2766477B1 (OSRAM)
JP (1) JP6329483B2 (OSRAM)
KR (1) KR20140108519A (OSRAM)
CN (1) CN103958676A (OSRAM)
AU (1) AU2012322811A1 (OSRAM)
BR (1) BR112014008873A2 (OSRAM)
CA (1) CA2852027A1 (OSRAM)
CL (1) CL2014000927A1 (OSRAM)
CO (1) CO7010783A2 (OSRAM)
HK (1) HK1200489A1 (OSRAM)
IL (1) IL232073A0 (OSRAM)
IN (1) IN2014MN00740A (OSRAM)
MX (1) MX2014004359A (OSRAM)
RU (1) RU2014117291A (OSRAM)
SG (2) SG10201510106PA (OSRAM)
TW (1) TW201321515A (OSRAM)
WO (1) WO2013055888A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
NZ608292A (en) 2010-09-09 2014-10-31 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
MX2014004359A (es) * 2011-10-12 2014-05-28 Synageva Biopharma Corp Proteina naglu humana recombinante y usos de la misma.
EP2785378B1 (en) 2011-12-02 2020-05-13 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
CA2912678C (en) * 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
TWI642782B (zh) * 2013-10-23 2018-12-01 健臻公司 重組醣蛋白及其用途
EP3143146B1 (en) * 2014-05-14 2020-05-20 Esteve Pharmaceuticals, S.A. Adenoassociated virus vectors for the treatment of lysosomal storage disorders
WO2015200675A1 (en) * 2014-06-25 2015-12-30 Shire Human Genetic Therapies, Inc. Generation of mannose-6-phosphate containing recombinant alpha-n-acetyl glucosaminidase
EP3185889B1 (en) * 2014-08-11 2020-07-15 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
WO2016054025A1 (en) * 2014-09-29 2016-04-07 Alexion Pharmaceuticals, Inc. Methods of treating mucopolysaccharidosis iiib (mpsiiib)
CN104524662B (zh) * 2014-12-31 2017-02-22 迈得医疗工业设备股份有限公司 一种医用针座组装的上料机构
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
US20190083583A1 (en) * 2016-01-29 2019-03-21 Alexion Pharmaceuticals, Inc. Enzyme replacement therapy in mucopolysaccharidosis iiib patients
IL305449B1 (en) 2016-04-15 2025-09-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
SG11202002457RA (en) 2017-09-22 2020-04-29 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
AU2021244191A1 (en) * 2020-03-23 2022-09-22 The University Of North Carolina At Chapel Hill AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB
CN111718947B (zh) * 2020-06-18 2022-08-23 舒泰神（北京）生物制药股份有限公司 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
US5897998A (en) 1997-08-04 1999-04-27 The University Of Georgia Research Foundation, Inc. Method for manipulating avian eggs
CA2307840C (en) 1997-10-16 2014-07-15 University Of Georgia Research Foundation, Inc. Protein production in transgenic avians
US7511120B2 (en) 1997-10-16 2009-03-31 Synageva Biopharma Corp. Glycosylated G-CSF obtained from a transgenic chicken
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US6679165B2 (en) 2002-05-22 2004-01-20 Shiny Shih Window adapted to a dater
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005107491A2 (en) * 2004-05-05 2005-11-17 Northeastern University Multi-lectin affinity chromatography and uses thereof
EP1981546B1 (en) 2006-02-06 2014-06-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
WO2008091311A1 (en) 2007-01-26 2008-07-31 Synageva Biopharma Corp Transgene expression in avians
JP5571576B2 (ja) * 2008-01-07 2014-08-13 シナジェバ・バイオファーマ・コーポレイション トリにおけるグリコシル化
WO2009131698A2 (en) 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
ES2576853T3 (es) * 2009-07-03 2016-07-11 Inserm - Institut National De La Santé Et De La Recherche Médicale Compuestos dirigidos al receptor del manosa 6-fosfato independiente de cationes
LT2588130T (lt) * 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
KR20130043166A (ko) * 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. 산필리포 증후군 b형의 치료
US8775146B2 (en) 2010-07-22 2014-07-08 Shire Human Genetic Therapies, Inc. Crystal structure of human alpha-N-acetylglucosaminidase
NZ608292A (en) 2010-09-09 2014-10-31 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
MX2014004359A (es) * 2011-10-12 2014-05-28 Synageva Biopharma Corp Proteina naglu humana recombinante y usos de la misma.

Similar Documents

Publication Publication Date Title
JP2014534962A5 (OSRAM)
RU2014117291A (ru) Рекомбинантный человеческий белок naglu и его применение
ES2690147T3 (es) Apelina pegilada y usos de la misma
Drago-Serrano et al. Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects
ES2281341T3 (es) Lectina humana recombinante que se une a manano.
ES2635990T3 (es) Nanopartículas de quitosano derivado dualmente y los métodos para fabricar y usar las mismas para la transferencia génica in vivo
ES2597954T3 (es) Conjugados de proteína de la coagulación sanguínea
US11697678B2 (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
US11241486B2 (en) Treatment of Middle East respiratory syndrome coronavirus
WO2009150284A2 (es) Conjugados de apo-a para la administración de compuestos biológicamente activos
JP2014521684A5 (OSRAM)
US20210386868A1 (en) Extracellular vesicles for replacement of urea cycle proteins & nucleic acids
JP2017529326A5 (OSRAM)
KR20170029576A (ko) 골형성단백질의 치료적 용도
CA3103847A1 (en) Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
US20200164049A1 (en) Treatment of human metapneumovirus
HRP20211197T1 (hr) Rekombinantni glikoproteini i njihova uporaba
US12138296B2 (en) Formulations for bovine granulocyte colony stimulating factor and variants thereof
ES2296529B1 (es) Composicion farmaceutica con promotores de absorcion.
US20230203507A1 (en) Modified mini-nucleosome core proteins and use in nucleic acid delivery
US20220233657A1 (en) Treatment of middle east respiratory syndrome coronavirus
US20200222511A1 (en) Treatment of merkel cell polyomavirus infection
ES2786025T3 (es) Productos conjugados de proteína-polímero
CN114712490A (zh) 包含重组酸性α-葡糖苷酶的配制品
KR20140130705A (ko) 체강액 저류 억제제